AC Immune SA 今日披露，已收到合作伙伴强生旗下杨森制药的通知，其针对阿尔茨海默病治疗药物开展的二期b阶段Retain临床试验，已决定暂时中止新患者的招募工作。
该决定由强生方面基于试验方案既定的标准流程作出，旨在对现有数据进行深入评估。目前，已完成入组患者的治疗与随访工作仍将按原计划持续推进，不受此次暂停招募的影响。
AC Immune SA 强调，此次暂停属于临床研究中的常规操作，公司将继续与强生保持密切沟通，并将在获得进一步信息后及时向市场更新情况。
AC Immune SA 今日披露，已收到合作伙伴强生旗下杨森制药的通知，其针对阿尔茨海默病治疗药物开展的二期b阶段Retain临床试验，已决定暂时中止新患者的招募工作。
该决定由强生方面基于试验方案既定的标准流程作出，旨在对现有数据进行深入评估。目前，已完成入组患者的治疗与随访工作仍将按原计划持续推进，不受此次暂停招募的影响。
AC Immune SA 强调，此次暂停属于临床研究中的常规操作，公司将继续与强生保持密切沟通，并将在获得进一步信息后及时向市场更新情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.